Aska Pharmaceutical Holdings Co., Ltd. · TSE:4886
Aska Pharmaceutical — Investor Presentation (May 2021)
31 slides from Aska Pharmaceutical's investor presentation, May 19, 2021
Slide 1: ASKA Pharmaceutical Holdings' Medium-Term Management Plan 2025
ASKA Pharmaceutical Holdings’ Medium-Term Management Plan 2025 Excerpts from the materials of FY2020 Financial Results (Fiscal year ended March 31, 2021) and ASKA Pharmaceutical Holdings’ Medium-Term Management Plan 2025 Presentation for Investors (held on May 19, 2021)
Slide 2: Vision of Medium-Term Management Plan 2025
Vision of Medium-Term Management Plan 2025 "Become a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company Equity-method ASKA Pharmaceutical subsidiaries Holdings Hataphar (Shareholding ratio : 24.9%) ASKA ASKA ASKA JAPAN GLASS Animal Health Pharmaceutical Pharma Medical IN
Slide 3: External Changes
External Changes ・Shrinking domestic pharmaceutical drug market ・Drastic reform of the drug pricing system (annual NHI price revisions, etc.) ・Impact of the new Corona Virus ・Pharmaceutical quality issues ・Advancement in medical technologies and expansion of medical needs Manufacturing and R&D Sales
Slide 4: The Foundation for Formulating the New Medium-Term Management Plan
The Foundation for Formulating the New Medium-Term Management Plan Ability to Social Specialty Specialty create contribution <Four Visions> 1 3 Expand business scope centered on Become the top domestic company regarding pharmaceutical products our specialty areas for pharmaceutical products 2 4 Impr
Slide 5: Aiming for Sustained Growth
Aiming for Sustained Growth ▲ Maintaining Growth and moving on to the Next Steps The Medium-Term Management Plan 2025 Numerical Targets Net sales 70 billion yen Operating profit rate 8% ROE8% 2025 Over 50 billion Net sales 30 billion New Medium-Term 20 billion scale Management Plan New drugs in the
Slide 6: Seven Strategies
Seven Strategies 1 <Specialty> 2 <Specialty> <Social contribution> <Ability to create> Enhancing Corporate Value by Continuous Creation of New Strengthening Initiatives in the Drugs through Advanced Drug Specialty Areas Discovery 3 <Ability to create> 4 <Specialty> <Ability to create> <Social contri
Slide 7: ASKA Pharmaceutical Co., Ltd. Numerical Targets
ASKA Pharmaceutical Co., Ltd. Numerical Targets Pharmaceutical business 51.3 billion yen Down in excess of Over 11 billion yen Net sales 10 billion yen for new products 50.3 billion yen due to NHI drug and introduction, price revisions, etc. etc. Cover the NHI drug price revisions (Estimate) (2021 —
Slide 8: Goals
<Specialty> <Social contribution> Enhancing Corporate Value by Strengthening Initiatives in the Specialty Area Goals Contribute to improving women's QOL as a leading company in the field of obstetrics and gynecology Contribute to the treatment of potential patients by promoting awareness-raising
Slide 9: Obstetrics and Gynecology Products by Life Stage
<Specialty> <Social contribution> Obstetrics and Gynecology Products by Life Stage Early Puberty Reproductive age Menopause Old age childhood Oral contraception LF111 ANGE NORLEVO Menopause HOLIN Iron deficiency anemia Riona (Co-Pro) Menstrual disorder PLANOVAR *RELUMINA is applying for additional I
Slide 10: Growth Factors
<Specialty> <Social contribution> Becoming a leading company in the field of obstetrics and gynecology Over 20 billion 16 billion 17 billion Existing products FREWELL AG Existing Uterine Jemina Existing products Contributing to Women's Active Participation fibroids Magsent products In society throug
Slide 11: Contributing to Uterine fibroids and Endometriosis through RELUMINA
<Specialty> <Social contribution> Contributing to Uterine fibroids and Endometriosis through RELUMINA (Millions of yen) RELUMINA Sales Trend Uterine fibroids treatment status 1,000 *Based on NHI drug price (Enlarged estimate from electronic receptacle data) 800 600 Patients diagnosed 400 With uterin
Slide 12: A New Option for Treatment of Endometriosis
<Specialty> <Social contribution> A New Option for Treatment of Endometriosis RELUMINA Tablets Endometriosis Phase III comparative study RELUMINA LEUPRORELIN VAS of Pelvic Pain Change from the baseline in the maximum (N=171) (N=164) * Application for Additional Indication of Endometriosis (January,
Slide 13: Responsibilities as a Leading Company in the Thyroid Area
<Specialty> <Social contribution> Responsibilities as a Leading Company in the Thyroid Area Disease awareness Initiatives in the Thyroid Area Butterfly ribbon badges ・Securing of stable supply Thyroid Area 10 billion yen ・Continue to raise awareness of diseases ・Cooperation with related academic soc
Slide 14: Responding to Unmet Medical Needs by RIFXIMA
<Specialty> <Social contribution> Responding to Unmet Medical Needs by RIFXIMA Revised version of Clinical Practice RIFXIMA Sales Trend 6,000 Guidelines for Cirrhosis. *Financial results base (Millions of yen) Strength of recommendation: 4,334 Strongly recommended Evidence level: A 3,780 2,478 (Appl
Slide 15: Continuous Creation of New Drugs through Advanced Drug Discovery
<Specialty> <Ability to create> Continuous Creation of New Drugs through Advanced Drug Discovery Open Innovation Alliance Industry, government, Licensing-in/out Shonan iPark and academia Global base Community Three Priority Areas Internal Obstetrics Medicine Urology and (Gastrointestinal and Thyroid
Slide 16: Development Pipeline
<Specialty> <Ability to create> Development Pipeline R&D Status (as of May 2021) Changes from the previous report Development code (Generic name) PhI PhII PhIII Application Approval Indication CDB-2914 (Ulipristal Acetate) Filed Uterine fibroids TAK-385 (Relugolix) Filed Endometriosis LF111 (Drospir
Slide 17: Drug Discovery Promotion (Alliance Activities)
<Specialty> <Ability to create> Drug Discovery Promotion (Alliance Activities) Joint R&D agreement for drug discovery Aim to create an aptamer drug targeting hormone receptors Option Agreement regarding the Treatment for Cervical Dysplasia Kino Pharma is conducting a Phase I Clinical Trial in Korea
Slide 18: Breakdown of Sales in Pharmaceutical Products
<Specialty> <Ability to create> Breakdown of Sales in Pharmaceutical Products Sales of Pharmaceutical Products 100% 90% Brand-name drugs ratio 80% 70% 70% 60% 50% 40% 30% 20% 10% 0% FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 Obstetrics and Gynecology Thyroid RIFXIMA Candesartan and others Brand-name
Slide 19: Overseas operations
<Ability to create> Overseas operations Goals Establish a business centered on the growing Asian market Leverage our accumulated know-how and technologies to improve quality and meet needs in the Asian market Efforts in the Asian Region 1. Business development in Vietnam ・Technical Support for Hat
Slide 20: Overseas operations
<Ability to create> Overseas operations [Completed acquisition of shares] On January 15, 2021, we completed the acquisition of 24.9% of the shares for Ha Tay Pharmaceutical Joint Stock Company (Hataphar) and completed the conversion of Hataphar into an equity-method affiliate. [Construction of new p
Slide 21: Total Healthcare: ASKA Animal Health
<Specialty> <Ability to create> <Social contribution> Total Healthcare ASKA Animal Health Co., Ltd. Description of Manufacture and sale of animal health products, feed and feed additives, raw materials, etc. Businesses Management Become an one of a kind company that supports the health of companion
Slide 22: Total Healthcare: Companion Animal Products
<Specialty> <Ability to create> <Social contribution> Total Healthcare ASKA Animal Health Co., Ltd. Market launch through the diversion of Companion animal-related pharmaceutical drugs to animal drugs ASKA Pharmaceutical Products 3% 5% Others MELCAZOLE🄬🄬 Fisheries medicine 9% Launched in Jan…
Slide 23: Total Healthcare: ASKA Pharma Medical
<Specialty> <Ability to create> <Social contribution> Total Healthcare ASKA Pharma Medical Co., Ltd. Description of Businesses Service of clinical testing and biologic testing Expansion of business through hair-growth diagnostics and thyroid disease Priority Targets testing NumericalTarget 500 milli
Slide 24: Total Healthcare: Healthcare Business
<Specialty> <Ability to create> <Social contribution> Total Healthcare ASKA Pharmaceutical Healthcare Business [aska-La folate multi-support] A one package/day well balanced supplement that includes folic acid and necessary nutrients. [YUINOBRUSH] A cervical cytology extraction instruments developed
Slide 25: Numerical Targets
<Specialty> <Ability to create> <Social contribution> Numerical Targets Net sales 70 billion yen Operating profit rate 8% ROE8% Diversification of earnings base in addition to expansion of domestic pharmaceutical business (Billions of yen) 70 700 18.8 27% 60 600 billion 4.8 9% 50 500 billion 40 400
Slide 26: Improving operational efficiency, cutting costs, and reinforcing our financial base
<Ability to create> Improving operational efficiency, cutting costs, and reinforcing our financial base Operating profit rate 8% ✔ Increase brand-name drugs ratio ✔ Initiatives related to SG&A Expenses Strengthen foundations Improve the Cost of sales DX Initiatives rate to less than 50% ✔ Establishm
Slide 27: Company that continues to be trusted
[Social contribution] <Specialty> <Ability to create> Foster an organizational culture that emphasizes thorough compliance and reliability / Human Resource Development for Realizing Growth Strategies Human resources capable of responding to new businesses and changes in the Active participation of d
Slide 28: Corporate Philosophy
Corporate Philosophy Contribute toward the improvement of people’s health and progress in society through the development of innovative products 28
Slide 29: Promotion of ESG management
[Social contribution] Promotion of ESG management [Corporate Philosophy] Contribute toward the improvement of people’s health and progress ASKA’s Main SDG Initiatives in society through the development of innovative products Establishment of Provide value to Identification ESG Committee Society and
Slide 30: Forward Looking Statement
Forward Looking Statement The forward-looking statements contained in this presentation are based the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual re
Slide 31: Inquiries
Inquiries Corporate Planning Department Tel : +81-3-5484-8366 e-mail : kouhou@aska-pharma.co.jp 31
ASKA Pharmaceutical Holdings — Investor Presentation (May 2021) on 6ix